 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678» |
- Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Clinical efficacy and durability of subcutaneous infliximab in patients with moderate-to-severe inflammatory bowel disease : a real-world data from a Korean multicentre prospective cohort study (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_1088;
Conclusion IFX-SC seems to be efficacious therapeutic option for patients with moderate-to-severe UC or CD patients in real-world settings. With a favorable drug survival and tolerable safety profile, it may facilitate individualized treatment with a good compliance.
- Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Maintenance of clinical, biochemical and transmural remission in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab. (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_1054;
Conclusion Switching from IV to SC infliximab in a selected cohort of IBD patients confirmed to be safe and effective in maintaining clinical, biochemical, and transmural remission. IUS is a useful, non-invasive and low-cost tool for periodic disease assessment in this subset of patients.
- Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
The persistence of subcutaneous infliximab is equivalent to intravenous form in patients with inflammatory bowel diseases. (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_1049;
In cases of poor tolerance to SC IFX, IV IFX re-initiation is effective. Switching to SC IFX is a therapeutic option for patients in remission on IV IFX.
- Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
One-year clinical outcomes of switching to subcutaneous infliximab in patients with inflammatory bowel disease on maintenance of intravenous infliximab therapy with or without remission: A multicentre cohort study (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_1003;
Conclusion Switching to SC IFX from IV IFX maintenance therapy demonstrated high treatment persistence and favourable safety profiles, irrespective of remission status at the time of switching. Patients in both remission or non-remission states showed significant improvement in pharmacokinetics and biomarkers, and/or stable disease activity indices.
- Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Effectiveness and safety of subcutaneous infliximab in Crohn (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_872;
67 % of patients with clinical inactive Crohn's disease at baseline remained in clinical remission until month 12. Conclusion Subcutaneous infliximab after previous failure and immunogenicity of intravenous infliximab was well tolerated and effective in a cohort of patients with refractory Crohn
- Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Impact of body mass index (BMI) on clinical outcomes and drug levels in patients with Crohn (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_865;
P3
1 Yarur A et al . Gastroenterology 2023;165:963
- Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure (Poster exhibition) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_847;
During the follow-up period, only two patients in group A discontinued SC infliximab, and only one complained of severe injection site reaction. Conclusion In UC patients who experience IV infliximab failure during maintenance treatment, switching to SC infliximab may be a promising option because of its efficacy and safety.
- Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Satellite Symposium 1d:Achieving endoscopic healing in IBD with subcutaneous infliximab: A path to improving long-term outcomes (A12) - Dec 21, 2023 - Abstract #ECCOIBD2024ECCO_IBD_502;
Conclusion In UC patients who experience IV infliximab failure during maintenance treatment, switching to SC infliximab may be a promising option because of its efficacy and safety. Sponsored by Healthcare Celltrion
- | Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Journal: Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study. (Pubmed Central) - Dec 1, 2023
Switching from IV to SC infliximab 120?mg every other week is safe and well accepted leading to low long-term risk of relapse. Tight monitoring and dose escalation should be recommended for patients receiving 10?mg/kg/6?weeks and 4?weeks, respectively.
- ||||| Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
New P4 trial: AMARETTO: Subcutaneous Infliximab After A Previous Intravenous Dose Optimization (clinicaltrials.gov) - Nov 1, 2023
P4, N=310, Not yet recruiting, Sponsor: Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
- ||||||| Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Trial completion: CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD) (clinicaltrials.gov) - Oct 23, 2023
P3, N=396, Completed, Sponsor: Celltrion
Tight monitoring and dose escalation should be recommended for patients receiving 10?mg/kg/6?weeks and 4?weeks, respectively. Active, not recruiting --> Completed
- | Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Journal: Therapeutic Drug Monitoring for Subcutaneous Infliximab? Too early to conclude. (Pubmed Central) - Oct 23, 2023
Active, not recruiting --> Completed No abstract available
- || Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Remsima SC (infliximab biosimilar SC) / Celltrion
PK/PD data, Review, Journal: Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview. (Pubmed Central) - Oct 16, 2023
CT-P13 subcutaneous (SC) was the first SC infliximab used for treatment of RA patients. Based on data from clinical studies and the real world, SC-infliximab is an attractive therapeutic option compared to IV formulations of infliximab based on its efficacy, pharmacokinetics, patient-reported outcomes and safety profile.
- | Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Enrollment open: PRIME: IBD Disease Course of Infliximab-na (clinicaltrials.gov) - Oct 3, 2023
P=N/A, N=120, Recruiting, Sponsor: Assistance Publique - H
Based on data from clinical studies and the real world, SC-infliximab is an attractive therapeutic option compared to IV formulations of infliximab based on its efficacy, pharmacokinetics, patient-reported outcomes and safety profile. Not yet recruiting --> Recruiting
- | Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
New trial: CHAMELEON: Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD (clinicaltrials.gov) - Oct 3, 2023
P=N/A, N=100, Not yet recruiting, Sponsor: Asan Medical Center
- ||||||| Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Trial completion: CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC) (clinicaltrials.gov) - Sep 28, 2023
P3, N=548, Completed, Sponsor: Celltrion
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Remsima SC (infliximab biosimilar SC) / Celltrion
A RETROSPECTIVE COHORT STUDY TO COMPARE THE EFFICACY, PHARMACOKINETICS AND SAFETY OF SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) INFLIXIMAB IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE (A1) - Sep 22, 2023 - Abstract #UEGW2023UEGW_3600;
SC switch should be considered in patients who are in established clinical remission on IV Infliximab as offering an effective and safe alternative, even in higher risk patients, with an increase in serum drug levels predictive of treatment success. The SC route displays different pharmacokinetic properties to IV which are favourable given the lower rates of treatment discontinuation.
- | Remsima SC (infliximab biosimilar SC) / Celltrion
Journal, Real-world evidence, Real-world: Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience. (Pubmed Central) - Sep 7, 2023
Treatment persistence at 6 months was 77.5%. Switching patients from IV infliximab to 120 mg fortnightly SC injections is a safe and effective option for the treatment of inflammatory bowel disease, including for those patients on dose-escalated infliximab or with active disease at the time of switch.
- | Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Trial initiation date: Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease: a randomised controlled trial - DISCUS-IBD (EUDRACT) - Sep 1, 2023
P3/4, N=120, Recruiting, Sponsor: The Alfred Hospital
Switching patients from IV infliximab to 120 mg fortnightly SC injections is a safe and effective option for the treatment of inflammatory bowel disease, including for those patients on dose-escalated infliximab or with active disease at the time of switch. Initiation date: Mar 2000 --> Mar 2023
- Network Meta-Analysis to Evaluate the Comparative Efficacy of Biologics for Maintenance Treatment of Adult Patients With Crohn (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_4041;
Initiation date: Mar 2000 --> Mar 2023 CT-P13 subcutaneous (SC) provides patients with a new opportunity for maintenance treatment of their disease...Among 8 comparator arms, infliximab (IFX) SC 120 mg every 2 weeks (Q2W) showed the highest odds ratio (95% confidence interval [CI]) vs. PBO (3.52 [2.18
- Remsima SC (infliximab biosimilar SC) / Celltrion
SWITCHING FROM INTRA-VENOUS TO SC INFLIXIMAB IS SAFE AND FEASIBLE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE SUFFERING FROM OBESITY: A POST-HOC ANALYSIS OF THE REMSWITCH STUDY (Science Lounge) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1928;
- Remsima SC (infliximab biosimilar SC) / Celltrion
REAL-LIFE EXPERIENCE OF THE EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. RESULTS FROM THE ENEIDA REGISTRY (Science Lounge) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1898;
- Remsima SC (infliximab biosimilar SC) / Celltrion
MAINTENANCE OF CLINICAL BIOCHEMICAL AND TRANSMURAL REMISSION IN IBD PATIENTS SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB (Science Lounge) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1840;
- Remsima SC (infliximab biosimilar SC) / Celltrion
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB FORMULATION DETERMINES A REDUCTION OF ANTIDRUG ANTIBODY LEVELS (Science Lounge) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1838;
- Remsima SC (infliximab biosimilar SC) / Celltrion, Entyvio (vedolizumab) / Takeda
TRANSITION FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB: ADHERENCE, SATISFACTION AND SAFETY PROFILE IN A COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE (Science Lounge) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1814;
- Remsima SC (infliximab biosimilar SC) / Celltrion
SUBCUTANEOUS INFLIXIMAB (Science Lounge) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1812;
- Remsima SC (infliximab biosimilar SC) / Celltrion
EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS (Science Lounge) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1771;
- Remsima SC (infliximab biosimilar SC) / Celltrion
HIGH SERUM SUBCUTANEOUS INFLIXIMAB LEVELS ARE ASSOCIATED WITH DEEP REMISSION IN PATIENTS WITH IBD (Auditorium 10) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1426;
- Remsima SC (infliximab biosimilar SC) / Celltrion, Entyvio (vedolizumab) / Takeda
TRANSITION FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB VERSUS VEDOLIZUMAB TREATMENT: A PROSPECTIVE MULTICENTER STUDY (A3) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1404;
- Remsima SC (infliximab biosimilar SC) / Celltrion
LONG-TERM EFFECTIVENESS AND ACCEPTABILITY OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: THE REMSWITCH-LT STUDY (A3) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1403;
- Remsima SC (infliximab biosimilar SC) / Celltrion, Entyvio (vedolizumab) / Takeda
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE RESULTS IN HIGHER TROUGH LEVELS, AND REDUCES DAY HOSPITAL VISITS AND MEDICAL EXPENSES (A3) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1402;
- Remsima SC (infliximab biosimilar SC) / Celltrion, Entyvio (vedolizumab) / Takeda
SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB AND VEDOLIZUMAB IN IBD IN CLINICAL REMISSION IS ASSOCIATED WITH A LOWER RATE OF DRUG DISCONTINUATION, DRUG OPTIMIZATION, AND REVERSE-SWITCH: AN INTERNATIONAL MULTICENTER STUDY (A3) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1401;
- Remsima SC (infliximab biosimilar SC) / Celltrion
SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY (Poster Stage 1) - Jul 8, 2023 - Abstract #UEGW2023UEGW_1208;
- || Remsima SC (infliximab biosimilar SC) / Celltrion
Review, Journal, Real-world evidence, Real-world: Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease. (Pubmed Central) - Jun 29, 2023
Switching may be advisable, given the clinical benefits of IFX SC and its potential to improve healthcare service capacity. There are several areas requiring further research, including the role of IFX SC in difficult-to-treat and refractory disease, and the feasibility of IFX SC monotherapy.
- || Remsima SC (infliximab biosimilar SC) / Celltrion
Clinical data, Journal: One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study. (Pubmed Central) - Jun 1, 2023
There are several areas requiring further research, including the role of IFX SC in difficult-to-treat and refractory disease, and the feasibility of IFX SC monotherapy. The SC IFX switch induced a higher 1-year durable remission rate than continuing IV IFX in patients with IBD during scheduled maintenance therapy, showing similar safety.
- || Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
Trial primary completion date: PEREM: A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima (clinicaltrials.gov) - May 31, 2023
P=N/A, N=400, Recruiting, Sponsor: Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
The SC IFX switch induced a higher 1-year durable remission rate than continuing IV IFX in patients with IBD during scheduled maintenance therapy, showing similar safety. Trial primary completion date: Aug 2022 --> Jun 2023
- Monitoring adherence to subcutaneous biologics for IBD care using digital technology (Hall 11) - May 30, 2023 - Abstract #BSG2023BSG_210;
Trial primary completion date: Aug 2022 --> Jun 2023 Aims and Following a successful NHS X bid for funding, a pilot proof of concept project to assess the feasibility and uptake of a digital technology (Health Beacon Digital Sharps Box
- | Remsima SC (infliximab biosimilar SC) / Celltrion
Journal: EFFECTIVENESS OF SWITCHING TO SUBCUTANEOUS INFLIXIMAB IN PAEDIATRIC INFLAMMATORY BOWL DISEASE PATIENTS ON INTRAVENOUS MAINTENANCE THERAPY. (Pubmed Central) - May 23, 2023
No newly-developed IFX-antibodies were detected and no adverse reactions or rescue therapies were recorded. Our real-world data support the feasibility of an elective switch to SC-IFX in PIBD as maintenance with potential advantages concerning medical resources and patient satisfaction.
- |||||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Zymfentra (infliximab-dyyb subcutaneous) / Celltrion
New trial: A Study to Evaluate the Safety of Remsima (clinicaltrials.gov) - May 19, 2023
P=N/A, N=864, Recruiting, Sponsor: Celltrion
- ||||| Remsima SC (infliximab biosimilar SC) / Celltrion
Clinical: Subcutaneous #infliximab demonstrates maintenance dose has 👍🏼 clinical benefit & easy use for moderate-to-severe active #CD 👏🏼#AGAIBDInfluencer #AGA #IBDVisible #IBDAwareness #IBDAdvocate #IBDResearch #IBDpatients #VoiceForIBD #IBD #Crohns #UC #HereForDDW @NMH_SHanauerMD (Twitter) - May 9, 2023
- |||| Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Remsima SC (infliximab biosimilar SC) / Celltrion
Clinical: Prof S Hanauer presents results of SC infliximab biosimilar CT-P13 for CD (LIBERTY)—both co primary endpoints at wk 54 (clinical remission and endoscopic response) were met, as well as key 2* endpoints—PK also quite favorable #DDW2023 @NMH_SHanauerMD @MLongMD @IBDMD (Twitter) - May 8, 2023
- | Remsima SC (infliximab biosimilar SC) / Celltrion
Journal: Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand? (Pubmed Central) - May 1, 2023
Progress will be made in biomarkers for the prediction of response and individualized dosing regimens. The advent of subcutaneous infliximab challenges the need for concomitant immunosuppression.
- Remsima SC (infliximab biosimilar SC) / Celltrion
Redefining Infliximab: the era of subcutaneous infliximab (Oceania B) - Apr 24, 2023 - Abstract #PANLAR2023PANLAR_331;
The advent of subcutaneous infliximab challenges the need for concomitant immunosuppression. Sponsored by CellTrion
- | Remsima SC (infliximab biosimilar SC) / Celltrion
Retrospective data, Journal, Combination therapy, Monotherapy: Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial. (Pubmed Central) - Apr 14, 2023
P1
Sponsored by CellTrion Pharmacokinetics, efficacy and immunogenicity were potentially comparable between SC infliximab monotherapy and combotherapy in biologic-na
- Remsima SC (infliximab biosimilar SC) / Celltrion
SWITCHING INFLIXIMAB TO SUBCUTANEOUS FROM INTRAVENOUS THERAPY (SWIMSUIT) (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_6349;
Conclusion Switching patients from IV to SC CT-P13 is safe, effective, and well-accepted with higher infliximab serum levels. The majority of the patients with no immunogenicity at baseline maintained this at W24.
- Remsima SC (infliximab biosimilar SC) / Celltrion
PERSISTENCE OF SUBCUTANEOUS INFLIXIMAB AFTER SWITCHING FROM INTRAVENOUS IN A FRENCH NATIONAL COHORT OF IBD PATIENTS IN REMISSION (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_6342;
Treatment switch was associated with an increase in IFX levels. These data are confirming the good efficacy and safety of IFX-SC after switch.
- Remsima SC (infliximab biosimilar SC) / Celltrion
SUBCUTANEOUS INFLIXIMAB: MIDTERM TREATMENT OUTCOMES IN PATIENTS WITH REFRACTORY CROHN (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_6341;
These data are confirming the good efficacy and safety of IFX-SC after switch. Conclusions Our midterm results with SC-IFX treatment demonstrate the treatment
- Remsima SC (infliximab biosimilar SC) / Celltrion
PREDICTORS OF IMMUNOGENICITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INFLIXIMAB: A POST HOC ANALYSIS OF THE RANDOMISED PHASE I CT-P13 SC STUDY (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_6285;
P1
1B ). Conclusion C trough level predicted ADA and NAb positivity in CD or UC pts, with levels ?4.695 ?g/mL significantly associated with lower rates of positivity, providing initial evidence on high zone tolerance of IFX.
- Remsima SC (infliximab biosimilar SC) / Celltrion
SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) AS MAINTENANCE THERAPY FOR ULCERATIVE COLIITS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY: RESULTS OF THE LIBERTY-UC STUDY (South Hall A, Poster Hall - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_6270;
P3
Among them, 438 patients (79.9%) responded to CT-P13 IV induction dosing and were randomised (294 in CT-P13 SC arm and 144 in placebo arm, respectively) at Week 10. The rate of clinical remission at Week 54 was significantly greater in CT P13 SC (43.2%) compared to placebo (20.8%) (P<0.0001).
- Inflectra (infliximab-dyyb) / Alvogen, Celltrion, Mundipharma, Egis, Nippon Kayaku, Pfizer, Remsima SC (infliximab biosimilar SC) / Celltrion
SUBCUTANEOUS INFLIXIMAB (CT-P13) AS MAINTENANCE THERAPY FOR CROHN'S DISEASE: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED STUDY (LIBERTY-CD). (W196 - McCormick Place) - Mar 23, 2023 - Abstract #DDW2023DDW_5965;
P3
No new safety concerns were found during treatment of CT-P13 SC. These results demonstrate that maintenance therapy with CT-P13 SC could provide both a large clinical benefit and the convenience of SC administration to moderately to severely active CD patients.